SCHEMBL13446962

SCHEMBL13446962

CC(=O)c1cccc(-n2c(C)cc(C=C3SC(=O)N(c4ccccc4)C3=O)c2C)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 8/20 0.68
▸ TCF4 P15884 1/20 0.66
▸ CTNNB1 P35222 1/20 0.66
▸ HDAC6 Q9UBN7 1/20 0.66
▸ MEN1 O00255 8/20 0.56
▸ KMT2A Q03164 8/20 0.56
▸ MAPT P10636 7/20 0.56
▸ ALDH1A1 P00352 5/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ CTDSP1 Q9GZU7 3/20 0.55
▸ APEX1 P27695 2/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ NSD2 O96028 1/20 0.55
▸ RECQL P46063 1/20 0.55
▸ RAB9A P51151 6/20 0.53
▸ MAPK1 P28482 3/20 0.53
▸ HTT P42858 1/20 0.53
▸ NPC1 O15118 6/20 0.51
▸ MYC P01106 2/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12009077 0.93 POLB (0.79) POLBTCF4CTNNB1HDAC6MEN1
SCHEMBL18545611 0.93 POLB (0.79) POLBTCF4CTNNB1HDAC6MEN1
SCHEMBL13446961 0.92 POLB (0.61) POLBTCF4CTNNB1HDAC6MEN1
SCHEMBL12009039 0.89 POLB (0.65) POLBTCF4CTNNB1HDAC6MEN1
SCHEMBL13446974 0.88 TCF4 (0.63) POLBTCF4CTNNB1HDAC6MEN1
SCHEMBL12009103 0.88 POLB (0.63) POLBTCF4CTNNB1HDAC6MEN1
SCHEMBL12009120 0.87 TCF4 (0.73) POLBTCF4CTNNB1HDAC6MEN1
SCHEMBL12009114 0.87 TCF4 (0.79) POLBTCF4CTNNB1HDAC6MEN1
SCHEMBL18545525 0.87 TCF4 (0.79) POLBTCF4CTNNB1HDAC6MEN1
SCHEMBL12006922 0.87 TCF4 (0.79) POLBTCF4CTNNB1HDAC6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 POLB 2397/4885TCF4 22/4885CTNNB1 1/4885
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 POLB 2088/4885TCF4 24/4885CTNNB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback